NEURELIS PRESENTED CLINICAL DATA SUPPORTING SEIZURE CLUSTER INTERVAL ANALYSIS AT THE EPILEPSY FOUNDATION PIPELINE CONFERENCE

Results of a post hoc analysis of Phase 3 clinical trial data may support a previously unrecognized effect of intermittent rescue therapy SAN DIEGO, June 7, 2022 /PRNewswire/ — Neurelis, Inc., announced findings from a novel, investigational analysis of VALTOCO┬« (diazepam nasal spray)…

Click here to view original post